In a remarkable example of drug repurposing, montelukast — commonly known as Singulair and already approved by the FDA for treating asthma and allergies — is showing significant promise in combating aggressive forms of cancer. The breakthrough could dramatically accelerate access to new cancer treatments. Because montelukast is already an approved medication

In a remarkable example of drug repurposing, montelukast — commonly known as Singulair and already approved by the FDA for treating asthma and allergies — is showing significant promise in combating aggressive forms of cancer. The breakthrough could dramatically accelerate access to new cancer treatments. Because montelukast is already an approved medication